Skip to main content

William Tillett

Dr William Tillett is a consultant rheumatologist at the Royal National Hospital for Rheumatic Diseases, Bath, UK, and senior lecturer in the Department of Pharmacy and Pharmacology at the University of Bath. He graduated from the University of Bristol, UK, with a BSc in Anatomical Science before undertaking his medical degree at the same institution. He undertook his doctoral fellowship in outcome measurement in psoriatic arthritis.

Dr Tillett’s current research interests center on the assessment of psoriatic arthritis (clinical, radiographic, and patient-reported outcomes), early detection of disease, and treatment strategies. He was awarded a EULAR Clinical Scientist award in 2015. He sits on the editorial board of the Journal of Rheumatology and the Versus Arthritis Inflammatory Arthritis Research Advisory Group.

Dr Tillet was a co-author of the British Society for Rheumatology 2012 guideline for the treatment of psoriatic arthritis with biologics, and currently co-chairs the guideline update committee. He is a co-chair of the international psoriatic arthritis Outcome Measurement in Rheumatology (OMERACT) working group. He is also a is a member of the international Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and trustee for the Bath Institute for Rheumatic Diseases (BIRD).

Syringe and white pills on blue background

10-07-2019 | Psoriatic arthritis | Highlight | Article

Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.